Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2001000651) ANTISENSE MODULATION OF G-ALPHA-i3 EXPRESSION
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2001/000651 International Application No.: PCT/US2000/000629
Publication Date: 04.01.2001 International Filing Date: 11.01.2000
Chapter 2 Demand Filed: 16.01.2001
IPC:
A61K 38/00 (2006.01) ,C12N 15/11 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
11
DNA or RNA fragments; Modified forms thereof
Applicants:
COWSERT, Lex, M. [US/US]; US (UsOnly)
ISIS PHARMACEUTICALS, INC. [US/US]; 2292 Faraday Avenue Carlsbad, CA 92008, US (AllExceptUS)
Inventors:
COWSERT, Lex, M.; US
Agent:
LICATA, Jane, Massey ; Licata & Tyrrell P.C. 66 E. Main Street Marlton, NJ 08053, US
Priority Data:
09/339,77525.06.1999US
Title (EN) ANTISENSE MODULATION OF G-ALPHA-i3 EXPRESSION
(FR) MODULATION ANTISENS DE L'EXPRESSION DE G-ALPHA-i3
Abstract:
(EN) Antisense compounds, compositions and methods are provided for modulating the expression of G-alpha-i3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G-alpha-i3. Methods of using these compounds for modulation of G-alpha-i3 expression and for treatment of diseases associated with expression of G-alpha-i3 are provided.
(FR) L'invention concerne des composés antisens, des compositions et des techniques permettant de moduler l'expression de G-alpha-i3. Ces compositions comprennent des composés antisens, notamment des oligonucléotides antisens, dirigés contre les acides nucléiques codant G-alpha-i3. L'invention concerne également des techniques d'utilisation de ces composés pour la modulation de l'expression de G-alpha-i3 et le traitement de maladies associées à l'expression de G-alpha-i3.
Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW
African Regional Intellectual Property Organization (ARIPO) (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)